Fig. 3From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experienceOverall survival for mCRPC patients treated with (AbiRT) and without (non-AbiRT) cytoreductive RT before abiraterone failure before (a) and after (b) propensity score matchingBack to article page